Insmed (NASDAQ:INSM) Reaches New 12-Month High After Analyst Upgrade

Insmed, Inc. (NASDAQ:INSM)’s stock price reached a new 52-week high during trading on Monday after Guggenheim raised their price target on the stock from $125.00 to $172.00. Guggenheim currently has a buy rating on the stock. Insmed traded as high as $146.91 and last traded at $145.86, with a volume of 288114 shares. The stock had previously closed at $145.10.

Several other research firms have also issued reports on INSM. Mizuho raised their price target on shares of Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Wells Fargo & Company lifted their price objective on shares of Insmed from $140.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. Truist Financial lifted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Finally, HC Wainwright lifted their price target on shares of Insmed from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $139.86.

Insider Buying and Selling

In related news, COO Roger Adsett sold 25,000 shares of the business’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer directly owned 105,637 shares of the company’s stock, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the business’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares in the company, valued at $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 535,320 shares of company stock worth $54,581,793 in the last ninety days. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV purchased a new stake in Insmed in the fourth quarter worth approximately $227,000. Baird Financial Group Inc. purchased a new stake in Insmed in the fourth quarter worth approximately $1,539,000. Cetera Investment Advisers boosted its stake in Insmed by 15.0% in the fourth quarter. Cetera Investment Advisers now owns 10,154 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 1,321 shares in the last quarter. Deutsche Bank AG boosted its stake in Insmed by 76.6% in the fourth quarter. Deutsche Bank AG now owns 488,966 shares of the biopharmaceutical company’s stock worth $33,758,000 after buying an additional 212,024 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in shares of Insmed by 9.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 529,049 shares of the biopharmaceutical company’s stock valued at $36,526,000 after purchasing an additional 44,928 shares during the period.

Insmed Stock Performance

The stock has a market cap of $30.93 billion, a PE ratio of -25.58 and a beta of 0.96. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business has a 50 day moving average price of $114.64 and a two-hundred day moving average price of $89.74.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. Insmed’s revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.